By: J. Chanslor
Procter & Gamble Pharmaceuticals is sponsoring a new study on the safety and efficacy of INGAP-peptide.
Researchers are currently recruiting new patients to attempt to create new beta cells in the pancreas and to restore the ability to produce insulin in people with type 1 diabetes.
The phase 2 study is interventional, randomized, double blinded, and placebo controlled.
At present, the type 1 arm of the study is full. However, there is still a need for some type 2s who would like to take part in the study.
Requirements for type 2s who wish to participate are:
- You must be between 35 and 70 years old
- You must have an A1C between 6.5% and 10%
- You must have a fasting C-peptide of less than 0.3 ng/ml
Clinical Trials-National Institutes of Health, November 2003